– Patent Covers Label-Mandated Dosing Scheme Across All Indications, Including Multiple Sclerosis; Previously Granted by the USPTO in 2023 –
NEW YORK , March 3, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX) , a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and...
– Top-Line Data from Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Expected by Year-End 2026 –
– Upfront Proceeds of USD 200 Million, with Potential for up to USD 200 Million in Additional Proceeds –
– Upfront Proceeds of USD 200 Million, with Potential for up to USD 200 Million in Additional Proceeds –
– Additional CALLIPER MRI Analyses Show Reductions for Vidofludimus Calcium in Acute and Chronic Inflammatory Disease Activity –
– Completed Enrollment for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected by End of 2026 –
NEW YORK , Nov. 26, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX) , a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and...